FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:790-796 September 12, 2002 Number 11 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Walsh, P. C. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background We evaluated symptoms and self-assessments of quality of life in men with localized prostate cancer who participated in a randomized comparison between radical prostatectomy and watchful waiting.

Methods Between 1989 and 1999, a group of Swedish urologists randomly assigned men with localized prostate cancer to radical prostatectomy or watchful waiting. In this follow-up study, we obtained information from 326 of 376 eligible men (87 percent) concerning certain symptoms, symptom-induced distress, well-being, and the subjective assessment of quality of life by means of a mailed questionnaire.

Results Erectile dysfunction (80 percent vs. 45 percent) and urinary leakage (49 percent vs. 21 percent) were more common after radical prostatectomy, whereas urinary obstruction (e.g., 28 percent vs. 44 percent for weak urinary stream) was less common. Bowel function, the prevalence of anxiety, the prevalence of depression, well-being, and the subjective quality of life were similar in the two groups.

Conclusions The assignment of patients to watchful waiting or radical prostatectomy entails different risks of erectile dysfunction, urinary leakage, and urinary obstruction, but on average, the choice has little if any influence on well-being or the subjective quality of life after a mean follow-up of four years.

Source Information

From the Department of Oncology and Pathology (G.S., F.H., P.W.D.) and the Department of Medical Epidemiology (P.W.D.), Karolinska Institutet, Stockholm; the Department of Urology and the Center for Assessment of Medical Technology, University Hospital, Örebro (F.H., J.-E.J.); Center for Surgical Sciences, Karolinska Institutet and Oncologic Center, Stockholm (J.A.); and the Department of Urology (B.J.N.) and the Department of Surgery, Regional Oncology Center (L.H.), University Hospital, Uppsala — all in Sweden.

Address reprint requests to Dr. Steineck at Clinical Cancer Epidemiology, Radiumhemmet, Karolinska Institutet, 17176 Stockholm, Sweden, or at gunnar.steineck{at}onkpat.ki.se.

Full Text of this Article

Related Letters:

Prostatectomy or Watchful Waiting in Prostate Cancer
Blanker M. H., Bierma-Zeinstra S. M.A., Schouten B. W.V., Coen J. J., Zietman A. L., Shipley W. U., Gambacorti-Passerini C. B., Sala E. A., Sonpavde G., Stern S. D., Bill-Axelson A., Holmberg L.
Extract | Full Text | PDF  
N Engl J Med 2003; 348:170-171, Jan 9, 2003. Correspondence

This article has been cited by other articles:

• Bill-Axelson, A., Holmberg, L., Filen, F., Ruutu, M., Garmo, H., Busch, C., Nordling, S., Haggman, M., Andersson, S.-O., Bratell, S., Spangberg, A., Palmgren, J., Adami, H.-O., Johansson, J.-E., for the Scandinavian Prostate Cancer Group Study N, (2008). Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial. JNCI J Natl Cancer Inst 100: 1144-1154 [Abstract] [Full Text]  
• Wilt, T. J. (2008). SPCG-4: A Needed START to PIVOTal Data to Promote and ProtecT Evidence-Based Prostate Cancer Care. JNCI J Natl Cancer Inst 100: 1123-1125 [Full Text]  
• Mucci, L. A., Pawitan, Y., Demichelis, F., Fall, K., Stark, J. R., Adami, H.-O., Andersson, S.-O., Andren, O., Eisenstein, A., Holmberg, L., Huang, W., Kantoff, P. W., Kim, R., Perner, S., Stampfer, M. J., Johansson, J.-E., Rubin, M. A. (2008). Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol. Biomarkers Prev. 17: 1682-1688 [Abstract] [Full Text]  
• Hegarty, J. M., Wallace, M., Comber, H. (2008). Uncertainty and Quality of Life Among Men Undergoing Active Surveillance for Prostate Cancer in the United States and Ireland. American Journal of Men's Health 2: 133-142 [Abstract]  
• Sanda, M. G., Dunn, R. L., Michalski, J., Sandler, H. M., Northouse, L., Hembroff, L., Lin, X., Greenfield, T. K., Litwin, M. S., Saigal, C. S., Mahadevan, A., Klein, E., Kibel, A., Pisters, L. L., Kuban, D., Kaplan, I., Wood, D., Ciezki, J., Shah, N., Wei, J. T. (2008). Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors. NEJM 358: 1250-1261 [Abstract] [Full Text]  
• Wilt, T. J., MacDonald, R., Rutks, I., Shamliyan, T. A., Taylor, B. C., Kane, R. L. (2008). Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer. ANN INTERN MED 148: 435-448 [Abstract] [Full Text]  
• Kirkham, A. P. S., Emberton, M., Hoh, I. M., Illing, R. O., Freeman, A. A., Allen, C. (2008). MR Imaging of Prostate after Treatment with High-Intensity Focused Ultrasound. Radiology 246: 833-844 [Abstract] [Full Text]  
• Kakehi, Y., Kamoto, T., Shiraishi, T., Ogawa, O., Suzukamo, Y., Fukuhara, S., Saito, Y., Tobisu, K.-i., Kakizoe, T., Shibata, T., Fukuda, H., Akakura, K., Suzuki, H., Shinohara, N., Egawa, S., Irie, A., Sato, T., Maeda, O., Meguro, N., Sumiyoshi, Y., Suzuki, T., Shimizu, N., Arai, Y., Terai, A., Kato, T., Habuchi, T., Fujimoto, H., Niwakawa, M. (2008). Prospective Evaluation of Selection Criteria for Active Surveillance in Japanese Patients with Stage T1cN0M0 Prostate Cancer. Jpn J Clin Oncol 0: hym161v1-7 [Abstract] [Full Text]  
• Vogl, T. J., Mayer, H. P., Zangos, S., Selby, J. B. Jr, Ackermann, H., Mayer, F. B. (2007). Prostate Cancer: MR Imaging guided Galvanotherapy Technical Development and First Clinical Results. Radiology 245: 895-902 [Abstract] [Full Text]  
• Shimizu, F., Igarashi, A., Fukuda, T., Kawachi, Y., Minowada, S., Ohashi, Y., Fujime, M. (2007). Decision Analyses in Consideration of Treatment Strategies for Patients with Biochemical Failure After Curative Therapy on Clinically Localized Prostate Cancer in the Prostate-Specific Antigen Era. Jpn J Clin Oncol 0: hym105v1-12 [Abstract] [Full Text]  
• Fradet, Y. (2007). Rebuttal: Should Canadians be offered systematic prostate cancer screening?: YES. cfp 53: 1140-1141 [Full Text]  
• Fradet, Y. (2007). Refutation: Devrait-on offrir aux Canadiens le depistage systematique du cancer de la prostate?: OUI. cfp 53: 1142-1143 [Full Text]  
• Labrecque, M., Legare, F., Cauchon, M. (2007). Should Canadians be offered systematic prostate cancer screening?: NO. cfp 53: 989-992 [Full Text]  
• Labrecque, M., Legare, F., Cauchon, M. (2007). Devrait-on offrir aux Canadiens le depistage systematique du cancer de la prostate?: NON. cfp 53: 994-997 [Full Text]  
• Bailey, D. E. Jr, Wallace, M. (2007). Critical Review: Is Watchful Waiting a Viable Management Option for Older Men With Prostate Cancer?. American Journal of Men's Health 1: 18-28 [Abstract]  
• Wong, Y.-N., Mitra, N., Hudes, G., Localio, R., Schwartz, J. S., Wan, F., Montagnet, C., Armstrong, K. (2006). Survival Associated With Treatment vs Observation of Localized Prostate Cancer in Elderly Men. JAMA 296: 2683-2693 [Abstract] [Full Text]  
• Albertsen, P. C. (2006). PSA Testing: Public Policy or Private Penchant?. JAMA 296: 2371-2373 [Full Text]  
• Smellie, W S A, Forth, J, Sundar, S, Kalu, E, McNulty, C A M, Sherriff, E, Watson, I D, Croucher, C, Reynolds, T M, Carey, P J (2006). Best practice in primary care pathology: review 4. J. Clin. Pathol. 59: 893-902 [Abstract] [Full Text]  
• Miller, D. C., Gruber, S. B., Hollenbeck, B. K., Montie, J. E., Wei, J. T. (2006). Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.. JNCI J Natl Cancer Inst 98: 1134-1141 [Abstract] [Full Text]  
• Blazeby, J. M., Avery, K., Sprangers, M., Pikhart, H., Fayers, P., Donovan, J. (2006). Health-Related Quality of Life Measurement in Randomized Clinical Trials in Surgical Oncology. JCO 24: 3178-3186 [Abstract] [Full Text]  
• Ribeiro, F. R., Jeronimo, C., Henrique, R., Fonseca, D., Oliveira, J., Lothe, R. A., Teixeira, M. R. (2006). 8q Gain Is an Independent Predictor of Poor Survival in Diagnostic Needle Biopsies from Prostate Cancer Suspects.. Clin. Cancer Res. 12: 3961-3970 [Abstract] [Full Text]  
• Gwede, C. K., McDermott, R. J. (2006). Prostate Cancer Screening Decision Making Under Controversy: Implications for Health Promotion Practice. Health Promot Pract 7: 134-146 [Abstract]  
• Klotz, L. (2005). Active Surveillance for Prostate Cancer: For Whom?. JCO 23: 8165-8169 [Abstract] [Full Text]  
• Stuart, M. E., Strite, S. A., Marantz, P. R., Hall, C. B., Derby, C. A., Liss, H. K., Elmore, J. G., Sonpavde, G., Bill-Axelson, A., Holmberg, L., Johansson, J.-E. (2005). Radical Prostatectomy versus Watchful Waiting. NEJM 353: 1298-1300 [Full Text]  
• Bradley, C. J., Neumark, D., Luo, Z., Bednarek, H., Schenk, M. (2005). Employment Outcomes of Men Treated for Prostate Cancer. JNCI J Natl Cancer Inst 97: 958-965 [Abstract] [Full Text]  
• Bill-Axelson, A., Holmberg, L., Ruutu, M., Haggman, M., Andersson, S.-O., Bratell, S., Spangberg, A., Busch, C., Nordling, S., Garmo, H., Palmgren, J., Adami, H.-O., Norlen, B. J., Johansson, J.-E., the Scandinavian Prostate Cancer Group Study No. 4, (2005). Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer. NEJM 352: 1977-1984 [Abstract] [Full Text]  
• (2004). Management of localised prostate cancer. DTB 42: 81-85 [Abstract] [Full Text]  
• Johnson, T. K., Gilliland, F. D., Hoffman, R. M., Deapen, D., Penson, D. F., Stanford, J. L., Albertsen, P. C., Hamilton, A. S. (2004). Racial/Ethnic Differences in Functional Outcomes in the 5 Years After Diagnosis of Localized Prostate Cancer. JCO 22: 4193-4201 [Abstract] [Full Text]  
• Kreicbergs, U., Valdimarsdottir, U., Onelov, E., Henter, J.-I., Steineck, G. (2004). Talking about Death with Children Who Have Severe Malignant Disease. NEJM 351: 1175-1186 [Abstract] [Full Text]  
• Potosky, A. L., Davis, W. W., Hoffman, R. M., Stanford, J. L., Stephenson, R. A., Penson, D. F., Harlan, L. C. (2004). Five-Year Outcomes After Prostatectomy or Radiotherapy for Prostate Cancer: The Prostate Cancer Outcomes Study. JNCI J Natl Cancer Inst 96: 1358-1367 [Abstract] [Full Text]  
• Paris, P. L., Andaya, A., Fridlyand, J., Jain, A. N., Weinberg, V., Kowbel, D., Brebner, J. H., Simko, J., Watson, J.E. V., Volik, S., Albertson, D. G., Pinkel, D., Alers, J. C., van der Kwast, T. H., Vissers, K. J., Schroder, F. H., Wildhagen, M. F., Febbo, P. G., Chinnaiyan, A. M., Pienta, K. J., Carroll, P. R., Rubin, M. A., Collins, C., van Dekken, H. (2004). Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 13: 1303-1313 [Abstract] [Full Text]  
• Johansson, J.-E., Andren, O., Andersson, S.-O., Dickman, P. W., Holmberg, L., Magnuson, A., Adami, H.-O. (2004). Natural History of Early, Localized Prostate Cancer. JAMA 291: 2713-2719 [Abstract] [Full Text]  
• Neugut, A. I., Grann, V. R. (2004). Waiting Time in Prostate Cancer. JAMA 291: 2757-2758 [Full Text]  
• Kao, J, Turian, J, Meyers, A, Hamilton, R J, Smith, B, Vijayakumar, S, Jani, A B (2004). Sparing of the penile bulb and proximal penile structures with intensity-modulated radiation therapy for prostate cancer. Br. J. Radiol. 77: 129-136 [Abstract] [Full Text]  
• Bott, S R J, Birtle, A J, Taylor, C J, Kirby, R S (2003). Prostate cancer management: (1) an update on localised disease. Postgrad. Med. J. 79: 575-580 [Abstract] [Full Text]  
• Sheffield, J. V.L., Larson, E. B. (2003). Update in General Internal Medicine. ANN INTERN MED 139: 285-293 [Full Text]  
• Sorum, P. C., Shim, J., Chasseigne, G., Bonnin-Scaon, S., Cogneau, J., Mullet, E. (2003). Why do Primary Care Physicians in the United States and France Order Prostate-Specific Antigen Tests for Asymptomatic Patients?. Med Decis Making 23: 301-313 [Abstract]  
• Bottomley, A., Thomas, R., Van Steen, K., Flechtner, H., de Graeff, A. (2003). Guidelines for the Use of Epoetin: Have Quality-of-Life Benefits Been Proven?. JCO 21: 2223-2223 [Full Text]  
• Wilt, T. J (2003). Radical prostatectomy reduced death from prostate cancer but not all cause mortality. Evid. Based Med. 8: 41-41 [Full Text]  
• Jewett, M. A.S., Fleshner, N., Klotz, L. H., Nam, R. K., Trachtenberg, J. (2003). Radical prostatectomy as treatment for prostate cancer. CMAJ 168: 44-45 [Full Text]  
• Siemens, D. R. (2003). Radical prostatectomy or watchful waiting in early prostate cancer?. CMAJ 168: 67-67 [Full Text]  
• Kakehi, Y. (2003). Watchful Waiting as a Treatment Option for Localized Prostate Cancer in the PSA Era. Jpn J Clin Oncol 33: 1-5 [Abstract] [Full Text]  
• Smith, R. A., Cokkinides, V., Eyre, H. J. (2003). American Cancer Society Guidelines for the Early Detection of Cancer, 2003. CA Cancer J Clin 53: 27-43 [Abstract] [Full Text]  
• Harris, R., Lohr, K. N. (2002). Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED 137: 917-929 [Abstract] [Full Text]  
• Chabner, B. A., Kaufman, D. (2002). Pity the Poor Consumer. The Oncologist 7: 475-476 [Full Text]  
• (2002). Prostatectomy vs. Watchful Waiting in Early Prostate Cancer. JWatch General 2002: 1-1 [Full Text]  
• Holmberg, L., Bill-Axelson, A., Helgesen, F., Salo, J. O., Folmerz, P., Haggman, M., Andersson, S.-O., Spangberg, A., Busch, C., Nordling, S., Palmgren, J., Adami, H.-O., Johansson, J.-E., Norlen, B. J., the Scandinavian Prostatic Cancer Group Study Numb, (2002). A Randomized Trial Comparing Radical Prostatectomy with Watchful Waiting in Early Prostate Cancer. NEJM 347: 781-789 [Abstract] [Full Text]  
• Walsh, P. C. (2002). Surgery and the Reduction of Mortality from Prostate Cancer. NEJM 347: 839-840 [Full Text]